Drug Trial Radar · NCT04926571
Dexamethasone and COVID-19 Inpatient Mortality
Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14,105
Actual
Start
Apr 1, 2020
Primary completion
Aug 27, 2021
Study completion Aug 27, 2021
Sponsor
- Lead sponsor
- Aetion, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 15, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.
Conditions
- Coronavirus
Interventions
Dexamethasone OralDrug
New users of Dexamethasone
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aetion, Inc.
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.